<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742973</url>
  </required_header>
  <id_info>
    <org_study_id>17039</org_study_id>
    <secondary_id>I4V-MC-JAIV</secondary_id>
    <nct_id>NCT03742973</nct_id>
  </id_info>
  <brief_title>A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of baricitinib in participants with primary&#xD;
      biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid&#xD;
      (UDCA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to enrollment futility.&#xD;
  </why_stopped>
  <start_date type="Actual">March 28, 2019</start_date>
  <completion_date type="Actual">September 26, 2019</completion_date>
  <primary_completion_date type="Actual">September 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Alkaline Phosphatase (ALP)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in Alkaline Phosphatase (ALP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Alkaline Phosphatase (ALP) &lt;1.67 x Upper Limit of Normal (ULN) (and at Least 15% Decrease From Baseline) and Total Bilirubin Level Less Than ULN</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of participants with alkaline phosphatase (ALP) &lt;1.67 x Upper Limit of Normal (ULN) (and at least 15% decrease from baseline) and total bilirubin level less than ULN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Itch Numeric Rating Scale (NRS)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in itch NRS. The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable.&quot; Overall severity of a participant's itching is indicated by circling the number that best describes the worst level of itching in the past 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fatigue NRS</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in fatigue NRS. The Fatigue NRS is a single-item, patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no fatigue&quot; and 10 representing &quot;as bad as you can imagine.&quot; Overall severity of a participant's fatigue is indicated by selecting the number that describes the worst level of fatigue during the past 7 days.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <arm_group>
    <arm_group_label>Baricitinib Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cohort A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 4 mg of Baricitinib orally once a day for 12 weeks. Cohort B was planned, but due to enrollment futility, the strategic decision was made to terminate the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cohort B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally. Cohort B was planned, but due enrollment futility, the strategic decision was made to terminate the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Baricitinib Cohort A</arm_group_label>
    <arm_group_label>Baricitinib Cohort B</arm_group_label>
    <other_name>LY3009104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo Cohort A</arm_group_label>
    <arm_group_label>Placebo Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of PBC (consistent with American Association for the Study of Liver&#xD;
             Disease (AASLD) and European Association for Study of the Liver (EASL) Practice&#xD;
             Guidelines; as demonstrated by the presence of at least 2 of the following 3&#xD;
             diagnostic factors:&#xD;
&#xD;
               -  History of elevated Alkaline Phosphatase (ALP) levels for at least 6 months&#xD;
&#xD;
               -  Positive antimitochondrial antibodies titer&#xD;
&#xD;
               -  Liver biopsy consistent with PBC&#xD;
&#xD;
          -  Have ALP ≥1.67 x ULN but ≤6 x Upper Limit Normal (ULN).&#xD;
&#xD;
          -  Taking UDCA for at least 52 weeks (stable dose for at least 12 weeks) prior to Week 0,&#xD;
             or have previously taken, but are intolerant (in the opinion of the investigator) to&#xD;
             UDCA and have not received UDCA for at least 12 weeks prior to Week 0.&#xD;
&#xD;
          -  Nonpregnant, nonbreastfeeding female participants of childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of other concomitant liver diseases including:&#xD;
&#xD;
               -  Hepatitis C virus (HCV) infection&#xD;
&#xD;
               -  Hepatitis B virus (HBV) infection&#xD;
&#xD;
               -  Primary sclerosing cholangitis&#xD;
&#xD;
               -  Alcoholic liver disease&#xD;
&#xD;
               -  Autoimmune liver disease other than PBC, such as overlap hepatitis&#xD;
&#xD;
               -  Nonalcoholic steatohepatitis&#xD;
&#xD;
               -  Gilbert's syndrome&#xD;
&#xD;
          -  Presence of clinical complications of PBC or clinically significant hepatic&#xD;
             decompensation, including:&#xD;
&#xD;
               -  Liver transplantation, current placement on a liver transplant list or current&#xD;
                  Model for End Stage Liver Disease (MELD) score ≥15&#xD;
&#xD;
               -  Portal hypertension with complications, including known gastric or esophageal&#xD;
                  varices, ascites, history of variceal bleeds or related therapeutic or&#xD;
                  prophylactic interventions (e.g., beta blockers, insertion of variceal bands or&#xD;
                  transjugular intrahepatic portosystemic shunt), or hepatic encephalopathy&#xD;
&#xD;
               -  Cirrhosis, including history or presence of one or more of the following:&#xD;
&#xD;
                    -  spontaneous bacterial peritonitis&#xD;
&#xD;
                    -  hepatocellular carcinoma&#xD;
&#xD;
               -  Hepatorenal syndrome (type I or II)&#xD;
&#xD;
          -  Have an estimated glomerular filtration rate (eGFR) based on the most recent available&#xD;
             serum creatinine of &lt;90 milliliters/minute/1.73 m2.&#xD;
&#xD;
          -  Have screening electrocardiogram (ECG) abnormalities that in the opinion of the&#xD;
             investigator or the sponsor are clinically significant and indicate an unacceptable&#xD;
             risk for the participant's participation in the study.&#xD;
&#xD;
          -  Have experienced any of the following within 12 weeks of screening: myocardial&#xD;
             infarction, unstable ischemic heart disease, stroke, or New York Heart Association&#xD;
             Stage III/IV heart failure.&#xD;
&#xD;
          -  Have a history of venous thromboembolism (VTE) (deep vein thrombosis/pulmonary&#xD;
             embolism [DVT/PE]).&#xD;
&#xD;
          -  Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,&#xD;
             endocrine, hematological, neurological, or neuropsychiatric disorders or any other&#xD;
             serious and/or unstable illness that, in the opinion of the investigator, could&#xD;
             constitute an unacceptable risk when taking investigational product or interfere with&#xD;
             the interpretation of data.&#xD;
&#xD;
          -  Have a current or recent (&lt;4 weeks prior to randomization) clinically serious&#xD;
             infection or any other active or recent infection that, in the opinion of the&#xD;
             investigator, would pose an unacceptable risk to the participant if participating in&#xD;
             the study.&#xD;
&#xD;
          -  Have had symptomatic herpes zoster infection within 12 weeks prior to randomization.&#xD;
&#xD;
          -  Have active tuberculosis (TB) disease determined on the basis of a positive medical&#xD;
             history, physical examination, or chest radiography (per local standard of care) or&#xD;
             latent TB infection (LTBI).&#xD;
&#xD;
          -  Have any of the following specific abnormalities based on screening central lab test&#xD;
             results:&#xD;
&#xD;
               -  Hemoglobin &lt;10 grams per deciliter (100.0 grams per liter)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt;3 x ULN&#xD;
&#xD;
               -  aspartate aminotransferase (AST) &gt;3 x ULN&#xD;
&#xD;
               -  alkaline phosphatase (ALP) &gt;6 x ULN&#xD;
&#xD;
               -  Total bilirubin level (TBL) &gt;ULN&#xD;
&#xD;
               -  Creatine phosphokinase (CPK) &gt; ULN&#xD;
&#xD;
               -  Serum albumin &lt; lower limit of normal (LLN)&#xD;
&#xD;
               -  International Normalized Ratio of Prothrombin Time (INR) &gt; ULN&#xD;
&#xD;
               -  Total white blood cell (WBC) count &lt;LLN&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt;LLN&#xD;
&#xD;
               -  Lymphocyte count &lt;LLN&#xD;
&#xD;
               -  Platelet (thrombocyte) count &lt;LLN&#xD;
&#xD;
          -  Are receiving unstable treatment for pruritus within 6 weeks prior to Week 0.&#xD;
&#xD;
          -  Have been treated with systemic (oral or parenteral) corticosteroids within 6 weeks&#xD;
             prior to Week 0.&#xD;
&#xD;
          -  Have received biologic treatments for an immunologic disease within 4 weeks of&#xD;
             screening.&#xD;
&#xD;
          -  Have received a Janus kinase (JAK) inhibitor.&#xD;
&#xD;
          -  Have received obeticholic acid.&#xD;
&#xD;
          -  Have received fenofibrate or other fibrates for the treatment of PBC.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California GI and Liver Centers (SCLC)</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis - Health Systems</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado School of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases/University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute for Digestive Health and Liver Disease at Mercy</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinical Investigations Group, LLC</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico, Medical Sciences Campus</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/liver-disease/JAIV#?postal=</url>
    <description>Click here for more information about this study: A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <results_first_submitted>September 18, 2020</results_first_submitted>
  <results_first_submitted_qc>September 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2020</results_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Janus kinase inhibitor</keyword>
  <keyword>JAK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03742973/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03742973/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility and cohort B is not reported due to early study termination based on enrollment futility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Baricitinib Cohort A</title>
          <description>Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Cohort A</title>
          <description>Participants received placebo orally once a day for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Cohort A</title>
          <description>Participants received placebo orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>.Baricitinib Cohort A</title>
          <description>Participants received 2 mg of Baricitinib tablet orally once a day for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline in ALP</title>
          <units>microgram/Liter (u/L)</units>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alkaline Phosphatase (ALP)</title>
        <description>Change from baseline in Alkaline Phosphatase (ALP)</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.</population>
        <group_list>
          <group group_id="O1">
            <title>Baricitinib Cohort A</title>
            <description>Participants received 2 mg of Baricitinib tablet orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Cohort A</title>
            <description>Participants received placebo orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alkaline Phosphatase (ALP)</title>
          <description>Change from baseline in Alkaline Phosphatase (ALP)</description>
          <population>Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Alkaline Phosphatase (ALP) &lt;1.67 x Upper Limit of Normal (ULN) (and at Least 15% Decrease From Baseline) and Total Bilirubin Level Less Than ULN</title>
        <description>Percentage of participants with alkaline phosphatase (ALP) &lt;1.67 x Upper Limit of Normal (ULN) (and at least 15% decrease from baseline) and total bilirubin level less than ULN.</description>
        <time_frame>Week 12</time_frame>
        <population>Zero participants with evaluable data was reported in cohort A due to protection of personal identifiable information based on enrollment futility.</population>
        <group_list>
          <group group_id="O1">
            <title>Baricitinib Cohort A</title>
            <description>Participants received 2 mg of Baricitinib tablet orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Alkaline Phosphatase (ALP) &lt;1.67 x Upper Limit of Normal (ULN) (and at Least 15% Decrease From Baseline) and Total Bilirubin Level Less Than ULN</title>
          <description>Percentage of participants with alkaline phosphatase (ALP) &lt;1.67 x Upper Limit of Normal (ULN) (and at least 15% decrease from baseline) and total bilirubin level less than ULN.</description>
          <population>Zero participants with evaluable data was reported in cohort A due to protection of personal identifiable information based on enrollment futility.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Itch Numeric Rating Scale (NRS)</title>
        <description>Change from baseline in itch NRS. The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable.&quot; Overall severity of a participant's itching is indicated by circling the number that best describes the worst level of itching in the past 7 days.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.</population>
        <group_list>
          <group group_id="O1">
            <title>Baricitinib Cohort A</title>
            <description>Participants received 2 mg of Baricitinib tablet orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Cohort A</title>
            <description>Participants received placebo orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Itch Numeric Rating Scale (NRS)</title>
          <description>Change from baseline in itch NRS. The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable.&quot; Overall severity of a participant's itching is indicated by circling the number that best describes the worst level of itching in the past 7 days.</description>
          <population>Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fatigue NRS</title>
        <description>Change from baseline in fatigue NRS. The Fatigue NRS is a single-item, patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no fatigue&quot; and 10 representing &quot;as bad as you can imagine.&quot; Overall severity of a participant's fatigue is indicated by selecting the number that describes the worst level of fatigue during the past 7 days.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.</population>
        <group_list>
          <group group_id="O1">
            <title>Baricitinib Cohort A</title>
            <description>Participants received 2 mg of Baricitinib tablet orally once a day for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Cohort A</title>
            <description>Participants received placebo orally once a day for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fatigue NRS</title>
          <description>Change from baseline in fatigue NRS. The Fatigue NRS is a single-item, patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no fatigue&quot; and 10 representing &quot;as bad as you can imagine.&quot; Overall severity of a participant's fatigue is indicated by selecting the number that describes the worst level of fatigue during the past 7 days.</description>
          <population>Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 Months</time_frame>
      <desc>Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility and cohort B is not reported due to early study termination based on enrollment futility.</desc>
      <group_list>
        <group group_id="E1">
          <title>Baricitinib Cohort A</title>
          <description>Participants received 2 mg of Baricitinib tablet orally once a day for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Cohort A</title>
          <description>Participants received placebo orally once a day for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Zero participants reported in cohort A due to protection of personal identifiable information based on enrollment futility and cohort B is not reported due to early study termination based on enrollment futility.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

